In the dose escalation portion of the Phase 1 clinical trial, 26 patients were enrolled, representing 15 different types of tumors. Ten patients received additional cycles of MGA271 treatment and all have had stable disease at the first tumor re-assessment. The most frequent adverse events in the trial were mild or moderate infusion reactions. No dose-limiting toxicity was observed.
"Servier is very pleased to take this additional step in the development of MGA271," stated Stephane Depil, M.D., Ph.D., who leads Oncology Research & Development at Servier. "We are encouraged by the initial potential for MGA271 in the treatment of a variety of B7-H3-expressing solid tumors."
"Servier is committed to developing first-in-class, innovative drugs in oncology, such as MGA271, which may ultimately deliver an innovative treatment for cancer patients," said Dr. Emmanuel Canet, President of Research and Development at Servier. "The various product candidates included in our two alliances with MacroGenics, including MGA271 and three oncology DART™ programs, are advancing as we had hoped."
Background on MGA271
MGA271 is a humanized, Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of molecules which are involved in immune regulation, and is over-expressed on a wide variety of solid tumor types. B7-H3 is over-expressed on differentiated tumor cells and cancer stem-like cells as well as on the supporting tumor vasculature and underlying tissues. MGA271 is designed to destroy all of these components of the cancer in addition to reducing its inhibitory properties on T cells.
Servier MGA271 Collaboration
In November 2011, MacroGenics entered into a collaboration agreement with Servier. Under this collaboration, Mac
|SOURCE MacroGenics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved